{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T00:42:07Z","timestamp":1793234527600,"version":"4.5.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,14]],"date-time":"2022-03-14T00:00:00Z","timestamp":1647216000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.eururo.2022.03.010","type":"journal-article","created":{"date-parts":[[2022,4,7]],"date-time":"2022-04-07T17:07:34Z","timestamp":1649351254000},"page":"223-232","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["Efficacy and Safety of AbobotulinumtoxinA in Patients with Neurogenic Detrusor Overactivity Incontinence Performing Regular Clean Intermittent Catheterization: Pooled Results from Two Phase 3 Randomized Studies (CONTENT1 and CONTENT2)"],"prefix":"10.1016","volume":"82","author":[{"given":"Michael","family":"Kennelly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sender","family":"Herschorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Abrams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kadir","family":"Onem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktor Kibanov","family":"Solomonov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"del Rosario Figueroa Coz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrei","family":"Manu-Marin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Giannantoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Vilain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magali","family":"Volteau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Denys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2022.03.010_b0005","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1002\/nau.23397","article-title":"An International Continence Society (ICS) report on the terminology for adult neurogenic lower urinary tract dysfunction (ANLUTD)","volume":"37","author":"Gajewski","year":"2018","journal-title":"Neurourol Urodyn"},{"issue":"Suppl 3","key":"10.1016\/j.eururo.2022.03.010_b0010","first-page":"S2","article-title":"Chapter 1: The conditions of neurogenic detrusor overactivity and overactive bladder","volume":"33","author":"Haab","year":"2014","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.eururo.2022.03.010_b0015","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.12968\/bjon.2016.25.18.S14","article-title":"An overview of urinary incontinence","volume":"25","author":"Bardsley","year":"2016","journal-title":"Br J Nurs"},{"key":"10.1016\/j.eururo.2022.03.010_b0020","first-page":"32","article-title":"Bladder wall thickness in the assessment of neurogenic bladder: a translational discussion of current clinical applications","volume":"4","author":"Sturm","year":"2016","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.eururo.2022.03.010_b0025","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.eururo.2009.04.028","article-title":"EAU guidelines on neurogenic lower urinary tract dysfunction","volume":"56","author":"St\u00f6hrer","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2022.03.010_b0030","series-title":"EAU guidelines: neuro-urology","author":"Blok","year":"2020"},{"key":"10.1016\/j.eururo.2022.03.010_b0035","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.rehab.2016.02.006","article-title":"Intermittent catheterization in neurologic patients: update on genitourinary tract infection and urethral trauma","volume":"59","author":"Biardeau","year":"2016","journal-title":"Ann Phys Rehabil Med"},{"key":"10.1016\/j.eururo.2022.03.010_b0040","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/nau.21003","article-title":"Epidemiology and healthcare utilization of neurogenic bladder patients in a US claims database","volume":"30","author":"Manack","year":"2011","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.eururo.2022.03.010_b0045","unstructured":"Allergan. Highlights of prescribing information: BOTOX\u00ae. Silver Spring, MD: US Food and Drug Administration; 2018. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/103000s5302lbl.pdf."},{"key":"10.1016\/j.eururo.2022.03.010_b0050","unstructured":"National Clinical Guideline Centre. Urinary incontinence in neurological disease: management of lower urinary tract dysfunction in neurological disease. Clinical guideline 148. London, UK: National Clinical Guideline Centre; 2012. https:\/\/www.nice.org.uk\/guidance\/cg148."},{"key":"10.1016\/j.eururo.2022.03.010_b0055","series-title":"Incontinence","year":"2017"},{"key":"10.1016\/j.eururo.2022.03.010_b0060","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.eururo.2011.07.002","article-title":"Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial","volume":"60","author":"Cruz","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2022.03.010_b0065","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1016\/j.juro.2012.01.125","article-title":"Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity","volume":"187","author":"Ginsberg","year":"2012","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2022.03.010_b0070","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.eururo.2007.09.034","article-title":"Neurogenic detrusor overactivity treated with English botulinum toxin A: 8-year experience of one single centre","volume":"53","author":"Del Popolo","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2022.03.010_b0075","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1111\/j.1464-410X.2006.06091.x","article-title":"What is the optimum dose of type A botulinum toxin for treating neurogenic bladder overactivity?","volume":"97","author":"Ruffion","year":"2006","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2022.03.010_b0080","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1080\/00365590601068835","article-title":"Efficacy and impact of botulinum toxin A on quality of life in patients with neurogenic detrusor overactivity: a randomised, placebo-controlled, double-blind study","volume":"41","author":"Ehren","year":"2007","journal-title":"Scand J Urol Nephrol"},{"key":"10.1016\/j.eururo.2022.03.010_b0085","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.eururo.2004.11.009","article-title":"Success of repeat detrusor injections of botulinum a toxin in patients with severe neurogenic detrusor overactivity and incontinence","volume":"47","author":"Grosse","year":"2005","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2022.03.010_b0090","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1111\/j.1464-410X.2009.08466.x","article-title":"Comparing two types of botulinum-A toxin detrusor injections in patients with severe neurogenic detrusor overactivity: a case-control study","volume":"104","author":"Grosse","year":"2009","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2022.03.010_b0095","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.eururo.2010.06.035","article-title":"Efficacy and tolerability of botulinum toxin type A in patients with neurogenic detrusor overactivity and without concomitant anticholinergic therapy: comparison of two doses","volume":"58","author":"Grise","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2022.03.010_b0100","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0090-4295(99)80384-7","article-title":"Quality of life of persons with urinary incontinence: development of a new measure","volume":"47","author":"Wagner","year":"1996","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2022.03.010_b0105","series-title":"Clinical trials with missing data: a guide for practitioners","first-page":"131","article-title":"Mixed models for repeated measures using categorical time effects (MMRM)","author":"Davis","year":"2014"},{"key":"10.1016\/j.eururo.2022.03.010_b0110","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.apmr.2007.02.009","article-title":"Reliability and validity of the Incontinence Quality of Life questionnaire in patients with neurogenic urinary incontinence","volume":"88","author":"Schurch","year":"2007","journal-title":"Arch Phys Med Rehabil"},{"key":"10.1016\/j.eururo.2022.03.010_b0115","doi-asserted-by":"crossref","first-page":"b2393","DOI":"10.1136\/bmj.b2393","article-title":"Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls","volume":"338","author":"Sterne","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.eururo.2022.03.010_b0120","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.juro.2018.10.012","article-title":"Long-term discontinuation of botulinum toxin A intradetrusor injections for neurogenic detrusor overactivity: a multicenter study","volume":"201","author":"Baron","year":"2019","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2022.03.010_b0125","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.eururo.2016.03.052","article-title":"More than 15 years of experience with intradetrusor onabotulinumtoxinA injections for treating refractory neurogenic detrusor overactivity: lessons to be learned","volume":"70","author":"Leitner","year":"2016","journal-title":"Eur Urol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283822016803?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283822016803?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T13:11:37Z","timestamp":1759583497000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283822016803"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["S0302283822016803"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2022.03.010","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Safety of AbobotulinumtoxinA in Patients with Neurogenic Detrusor Overactivity Incontinence Performing Regular Clean Intermittent Catheterization: Pooled Results from Two Phase 3 Randomized Studies (CONTENT1 and CONTENT2)","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2022.03.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}